Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 29.
doi: 10.1007/s12013-025-01850-y. Online ahead of print.

6-Methoxydihydrosanguinarine Suppresses the Proliferation of Non-small Cell Lung Cancer Cells through Elevation of ROS and Activation of IRE1/JNK Signaling

Xiao Qi  1 , Chong Niu  1 , Zi-Zheng Zhang  2 , Meng-Ru Chen  2 , Feng-Ze Wang  3 , Hong-Rong Fei  4
Affiliations

6-Methoxydihydrosanguinarine Suppresses the Proliferation of Non-small Cell Lung Cancer Cells through Elevation of ROS and Activation of IRE1/JNK Signaling

Xiao Qi et al. Cell Biochem Biophys. .
No abstract available

Keywords: 6-Methoxydihydrosanguinarine; Akt; JNK; NSCLC; ROS; YAP.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing Interests: The authors declare no competing interests.

References

    1. Zhang, D., Wang, Y., Yu, P., Sun, J., Li, J., Hu, Y., et al. (2025). Scutellarein inhibits lung cancer growth by inducing cell apoptosis and inhibiting glutamine metabolic pathway. Journal of Ethnopharmacology, 337(Pt 2), 118999. https://doi.org/10.1016/j.jep.2024.118999 - DOI - PubMed
    1. Bizuayehu, H. M., Ahmed, K. Y., Kibret, G. D., Dadi, A. F., Belachew, S. A., Bagade, T., et al. (2024). Global disparities of cancer and its projected burden in 2050. JAMA Netw Open, 7(11), e2443198. https://doi.org/10.1001/jamanetworkopen.2024.43198 - DOI - PubMed - PMC
    1. Waliany, S., Lin, J. J., & Gainor, J. F. (2025). Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer. Trends Cancer, S2405-8033(25), 00006–8. https://doi.org/10.1016/j.trecan.2025.01.005 - DOI
    1. Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., et al. (2022). Cancer treatment and survivorship statistics, 2022. C Ca: A Cancer Journal for Clinicians, 72(5), 409–436. https://doi.org/10.3322/caac.21731 - DOI
    1. von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., et al. (2023). Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology, 41(23), 3881–3890. https://doi.org/10.1200/JCO.22.02763 - DOI - PubMed

LinkOut - more resources